Diseases [C] » Nervous System Diseases [C10] » Autoimmune Diseases of the Nervous System
Diseases [C] » Immune System Diseases [C20] » Autoimmune Diseases » Autoimmune Diseases of the Nervous System
Description
Disorders caused by cellular or humoral immune responses primarily directed towards nervous system autoantigens. The immune response may be directed towards specific tissue components (e.g., myelin) and may be limited to the central nervous system (e.g., MULTIPLE SCLEROSIS) or the peripheral nervous system (e.g., GUILLAIN-BARRE SYNDROME). MeSH
Hierarchy View
Subtype Terms (8)
Anti-N-Methyl-D-Aspartate Receptor Encephalitis
2 drugs (1 approved, 1 experimental)
Demyelinating Autoimmune Diseases, CNS
3 drugs (2 approved, 1 experimental)
Myasthenia Gravis
67 drugs (44 approved, 23 experimental)
Nervous System Autoimmune Disease, Experimental
Polyradiculoneuropathy
22 drugs (16 approved, 6 experimental)
Stiff-Person Syndrome
15 drugs (13 approved, 2 experimental)
Uveomeningoencephalitic Syndrome
3 approved drugs
Vasculitis, Central Nervous System
8 drugs (6 approved, 2 experimental)
Phase 4 Indicated Drugs (1)
Phase 3 Indicated Drugs (2)
Organization Involved with Phase 4 Indications (3)
Organization Involved with Phase 2 Indications (14)
Organization Involved with Phase 1 Indications (2)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
